Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26313193 | 1.00 | CA12 (0.48) | CA12CA1CA9CA2MGLL | |
| SCHEMBL7609631 | 1.00 | CA12 (0.48) | CA12CA1CA9CA2MGLL | |
| SCHEMBL5427583 | 1.00 | CA12 (0.48) | CA12CA1CA9CA2MGLL | |
| SCHEMBL4997835 | 0.91 | CA12 (0.58) | CA12CA1CA9CA2KDM5A | |
| SCHEMBL7611421 | 0.89 | FAAH (0.57) | MMP2FAAH | |
| SCHEMBL7611413 | 0.89 | FAAH (0.57) | MMP2FAAH | |
| SCHEMBL4995204 | 0.85 | CA12 (0.52) | CA12CA1CA9CA2KDM5A | |
| SCHEMBL22683217 | 0.83 | CA12 (0.48) | CA12CA1CA9CA2MGLL | |
| SCHEMBL13844086 | 0.83 | CA12 (0.61) | CA12CA1CA9CA2MGLL | |
| SCHEMBL23010518 | 0.82 | CA12 (0.38) | CA12CA1CA9CA2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806350-A2 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO International B.V. (NL) | 2007-07-11 | — | — | EP | disclosed |
| US-6652834-B2 | Tensioactive properties, long lasting activity in the blood pool | BRACCO INTERNATIONAL B.V. (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO INTERNATIONAL B.V. | 2002-07-25 | — | — | US | disclosed |
| US-6342598-B1 | BLOOD-POOL CONTRAST AGENTS OF OUTSTANDING LONG LIFE IN CIRCULATION | BRACCO INTERNATIONAL B.V. (NL) | 2002-01-29 | — | — | US | disclosed |
| EP-1153029-A2 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000030688-A2 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | SLC39A14, HAMP, PICALM | CA12 674/4885CA1 589/4885CA9 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.